Roche, Hetero donate antiflu meds in India; Sanofi nabs Canadian OK for Multaq;

> Roche's Indian unit and India's Hetero Drugs together donated 100,000 doses of Tamiflu/oseltamivir to the Indian government as the H1N1 flu spreads in the country. Report

> Sanofi-Aventis won Canadian approval for its atrial fibrillation remedy Multaq, the only new treatment for managing the condition in 20 years. Release

> The federal agency that manages Medicare said most beneficiaries would see a small increase in their drug-plan premiums next year. Report

> A CDC study found that more than twice as many children are accidentally poisoned with prescription or over-the-counter medicines as with household consumer products. Report

> Discovery Laboratories said that CEO Robert Capetola has resigned and will be replaced on an interim basis by Chairman W. Thomas Amick. Report

Biotech News

> Shares of BioSante Pharmaceuticals shot up 69 percent in pre-market trading after the developer announced positive late-stage safety data for its female dysfunction treatment LibiGel. Report

> Score one for Wisconsin's biotech economic development team. Dangling close to a million dollars in new investment capital and a loan, the state hooked the Boston-based biotech Flex Biomedical, which will now move from the big biotech hub in Bean Town to Madison. Report

> The Biotechnology Industry Organization and Thomson Reuters stuck their fingers into the market air and detected distinct signs of a growing wind filling the sails of the nation's biotech industry. Report

> The fast-growing Cambridge, MA-based Constellation Pharmaceuticals has a new CEO and a fresh injection of cash to fund its work in the field of epigenetics. The company has named Mark A. Goldsmith, M.D., Ph.D., to the top post and closed on $17 million in fresh venture funds, the third tranche of its Series A. Report

And Finally... Scientists said they have found a drug compound that attacks in a new way the stem cells that fuel tumor growth, opening a path to a new type of anti-cancer treatment. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.